After further analysis of data collected after the interim assessment, Biogen has decided to file for FDA approval of aducanumab, the thought dead Alzheimer’s drug that failed a futility analysis in March. Biogen share price has been on a steady climb since the announcement this morning, and is up more than 40% already.
Click here for the full story from FierceBiotech.